Annovis Bio, Inc. (ANVS)

USD 1.61

(2.55%)

Net Debt Summary of Annovis Bio, Inc.

Annovis Bio, Inc.'s latest annual net debt in 2023 was -5.75 Million USD , up 79.72% from previous year.
Annovis Bio, Inc.'s latest quarterly net debt in 2024 Q2 was -3.99 Million USD , down -27.44% from previous quarter.
Annovis Bio, Inc. reported annual net debt of -28.37 Million USD in 2022, up 37.89% from previous year.
Annovis Bio, Inc. reported annual net debt of -45.68 Million USD in 2021, down -465.8% from previous year.
Annovis Bio, Inc. reported quarterly net debt of -3.13 Million USD for 2024 Q1, up 45.49% from previous quarter.
Annovis Bio, Inc. reported quarterly net debt of -5.75 Million USD for 2023 Q4, up 9.44% from previous quarter.

Annual Net Debt Chart of Annovis Bio, Inc. (2023 - 2017)

Historical Annual Net Debt of Annovis Bio, Inc. (2023 - 2017)

Year	Net Debt	Net Debt Growth
2023	-5.75 Million USD	79.72%
2022	-28.37 Million USD	37.89%
2021	-45.68 Million USD	-465.8%
2020	-8.07 Million USD	-1721.58%
2019	497.94 Thousand USD	1510.14%
2018	-35.31 Thousand USD	89.84%
2017	-347.47 Thousand USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	-3.99 Million USD	-27.44%
2024 Q1	-3.13 Million USD	45.49%
2023 Q4	-5.75 Million USD	9.44%
2023 Q2	-15.72 Million USD	6.17%
2023 FY	-5.75 Million USD	79.72%
2023 Q1	-16.75 Million USD	40.94%
2023 Q3	-6.35 Million USD	59.59%
2022 Q3	-31.98 Million USD	11.08%
2022 Q1	-42.66 Million USD	6.6%
2022 FY	-28.37 Million USD	37.89%
2022 Q4	-28.37 Million USD	11.28%
2022 Q2	-35.97 Million USD	15.69%
2021 Q4	-45.68 Million USD	3.73%
2021 Q2	-49.22 Million USD	-778.56%
2021 FY	-45.68 Million USD	-465.8%
2021 Q1	-5.6 Million USD	30.61%
2021 Q3	-47.45 Million USD	3.59%
2020 Q1	-11.12 Million USD	-2333.25%
2020 Q3	-8.84 Million USD	9.45%
2020 Q4	-8.07 Million USD	8.66%
2020 FY	-8.07 Million USD	-1721.58%
2020 Q2	-9.76 Million USD	12.2%
2019 Q1	159.28 Thousand USD	551.07%
2019 Q2	392.22 Thousand USD	146.25%
2019 Q3	442.02 Thousand USD	12.7%
2019 Q4	497.94 Thousand USD	12.65%
2019 FY	497.94 Thousand USD	1510.14%
2018 Q1	347.47 Thousand USD	0.0%
2018 FY	-35.31 Thousand USD	89.84%
2018 Q4	-35.31 Thousand USD	0.0%
2017 FY	-347.47 Thousand USD	0.0%

Peer Net Debt Comparison of Annovis Bio, Inc.

Name	Net Debt	Net Debt Difference
ADC Therapeutics SA	-154.22 Million USD	96.269%
Alto Neuroscience, Inc.	68.91 Million USD	108.35%
Biohaven Pharmaceutical Holding Company Ltd.	-218.84 Million USD	97.37%
Ginkgo Bioworks Holdings, Inc.	-707.09 Million USD	99.186%
Nuvation Bio Inc.	-38.64 Million USD	85.108%
Nuvation Bio Inc.	-38.64 Million USD	85.108%
Arcus Biosciences, Inc.	-116 Million USD	95.039%
Zymeworks Inc.	-130.83 Million USD	95.602%